高级搜索

25-羟基维生素D与结直肠癌关系的Meta分析

于慧会, 魏立璇, 刘运泳, 邢晓静

于慧会, 魏立璇, 刘运泳, 邢晓静. 25-羟基维生素D与结直肠癌关系的Meta分析[J]. 肿瘤防治研究, 2015, 42(04): 394-398. DOI: 10.3971/j.issn.1000-8578.2015.04.017
引用本文: 于慧会, 魏立璇, 刘运泳, 邢晓静. 25-羟基维生素D与结直肠癌关系的Meta分析[J]. 肿瘤防治研究, 2015, 42(04): 394-398. DOI: 10.3971/j.issn.1000-8578.2015.04.017
YU Huihui, WEI Lixuan, LIU Yunyong, XING Xiaojing. Meta-analysis of Relationship Between Blood 25-hydroxyvitamin D Level and Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 394-398. DOI: 10.3971/j.issn.1000-8578.2015.04.017
Citation: YU Huihui, WEI Lixuan, LIU Yunyong, XING Xiaojing. Meta-analysis of Relationship Between Blood 25-hydroxyvitamin D Level and Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 394-398. DOI: 10.3971/j.issn.1000-8578.2015.04.017

25-羟基维生素D与结直肠癌关系的Meta分析

基金项目: 国家自然科学基金项目(181201968);辽宁省科技公关项目(2012225016);辽宁省自然科学基金 (201102111)
详细信息
    作者简介:

    于慧会(1985-),女,硕士,研究实习员,主要从事肿瘤流行病学研究

    通讯作者:

    邢晓静,E-mail:13940066477@163.com

  • 中图分类号: R735.3

Meta-analysis of Relationship Between Blood 25-hydroxyvitamin D Level and Colorectal Cancer

  • 摘要: 目的 探讨25-羟基维生素D水平与结直肠癌的关系,为结直肠癌的防治和病因探索提供证据。方法 检索MEDLINE、EMBASE等大型数据库中2003至2013年发表的有关25-羟基维生素D水平与结直肠癌关系的前瞻性研究文献。采用Meta分析方法,应用Stata11.0软件评价25-羟基维生素D水平与结直肠癌的关系。结果 (1)血液25-羟基维生素D水平最高组与最低组在结直肠癌组与对照组间比较差异有统计学意义(RR= 0.79,95%CI: 0.65~0.95)。(2)地区亚组分析显示,血液25-羟基维生素D水平最高组与最低组间比较差异均无统计学意义。美洲组RR=0.78(95%CI: 0.60~1.02),欧洲组RR=0.77(95%CI: 0.56~1.06),亚洲组RR=0.89(95%CI: 0.52~1.50)。(3)Egger's检验法检验无统计学意义(P>0.05),Begg's漏斗图基本对称,所以没有显著的发表偏倚。结论 血液25-羟基维生素D水平与结直肠癌存在联系,补充维生素D对结直肠癌的预防和治疗有一定意义。

     

    Abstract: Objective To investigate the association between blood 25-hydroxyvitamin(OH) D level and colorectal cancer, and to provide evidence for the prevention strategy and understanding of the etiology of colorectal cancer. Methods MEDLINE, EMBASE and other large databases were searched. The prospectivestudies about the association of 25-(OH) D and colorectal cancer published from 2003 to May 2013 were selected. A comprehensive quantitative analysis was performed by Meta-analysis method with Stata11.0 software. Results Meta-analysis results showed that the pooled RRs of colorectal cancer for the highest versus lowest categories of blood 25-(OH)D levels were 0.79(95%CI:0.65~0.95). Stratifying by geographic region, the pooled RRs of colorectal cancer for the highest versus lowest categories of 25-(OH)D levels for studies conducted in the United States, Europe and Asia were 0.78(95%CI:0.60-1.02),0.77(95%CI:0.56-1.06),0.89(95%CI:0.52-1.50), respectively. Egger's test showed that the publication bias had no statistical significance (P>0.05). Begg's funnel plot was symmetric figure, so there was no significant publication bias. Conclusion Blood 25-(OH)D level is associated with the risk of colorectal cancer. Intake of Vitamin D might be useful for the prevention and treatment of colorectal cancer.

     

  • [1] Chen Q, Liu ZC, Chen LP, et al. An analysis of incidence and mortality of colorectal cancer in china, 2003~2007[J]. Zhongguo Zhong Liu, 2012, 21(3):179-82. [陈琼, 刘志才, 程兰平, 等. 20 03~2007年中国结直肠癌发病与死亡分析[J]. 中国肿瘤, 20 12, 21(3): 179-82.]
    [2] Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer?[J]. Int J Epidemiol, 1980, 9(3): 227-31.
    [3] Evans SR, Shchepotin EI, Young H, et al. 1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1, 2-dimethylhydrazine-induced colon carcinogenesis model[J]. Int J Oncol, 2000, 16(6):1249-54.
    [4] Newmark HL, Yang K, Kurihara N, et al. Western-style dietinduced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer[J]. Carcinogenesis, 2009, 30(1): 88-92.
    [5] Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy[J]. Cancer Res, 2000, 60(8): 2304-12.
    [6] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. Int J Surg, 2010, 8(5): 336-41.
    [7] GA Wells, B Shea, D O’Connell, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses[ S] http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp. Accessed 30 April 2013.
    [8] Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis[ J] Stat Med, 2002, 21(11): 1539-58.
    [9] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414): 557-60.
    [10] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997, 315(7109): 629-34.
    [11] Neuhouser ML, Manson JE, Millen A, et al. The influence of health and lifestyle characteristics on the relation of serum 25 -hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women[J]. Am J Epidemiol, 2012, 175(7): 673-84.
    [12] Lee JE, Li H, Chan AT, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians’ Health Study and a metaanalysis of prospective studies[J]. Cancer Prev Res (Phila), 2011, 4( 5): 735-43.
    [13] Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested casecontrol study[J]. BMJ, 2010, 340: b5500.
    [14] Wu K, Feskanich D, Fuchs CS, et al. A nested case-control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer[J]. J Natl Cancer Inst, 2007, 99(14): 1120-9.
    [15] Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(9): 1502-8.
    [16] Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study[J]. Br J Cancer, 2007, 97(3): 446-51.
    [17] Weinstein SJ, Yu K, Horst RL, et al. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men[J]. Am J Epidemiol, 2011, 173(5): 499-508.
    [18] Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25 -hydroxyvitamin D levels and the risk of colorectal cancer: The multiethnic cohort study[J]. Cancer Epidemiol Biomarkers Prev, 20 10, 19(1): 130-4.
    [19] Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial[J]. BMJ, 2003, 326(7387): 469.
    [20] Giovannucci E. Epidemiology of vitamin D and colorectal cancer [J] Anticancer Agents Med Chem, 2013, 13(1): 11-9.
    [21] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 20 11, 96(7): 1911-30.
    [22] Slattery ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer[J]. Int J Cancer, 20 04, 111(5): 750-6.
    [23] Slattery ML, Wolff RK, Herrick JS, et al. Calcium, vitamin D, VDR genotypes,and epigenetic and genetic changes in rectal tumors[J]. Nutr Cancer, 2010, 62(4): 436-42.
    [24] Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a metaanalysis of 26,335 cases from 60 observational studies[J]. Nutr Cancer, 2009, 61(1): 47-69.
    [25] Hu ZY, Zhou YP, Li SW, et al. 1,25-digydroxyvitaminD3 enhanced killing effect of carboplatin on growth in lung cancer cell A549[J]. Zhong Liu Fang Zhi Yan Jiu, 2013, 40(2): 125-30. [胡志勇, 周逸 鹏, 黎书炜, 等. 1,25-二羟基维生素D3增强卡铂对人肺癌A549 细胞的杀伤效果[J]. 肿瘤防治研究, Zhong Liu Fang Zhi Yan Jiu, 20 13, 40(2): 125-30.]
计量
  • 文章访问数:  1545
  • HTML全文浏览量:  324
  • PDF下载量:  30437
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-03-18
  • 修回日期:  2014-10-13
  • 刊出日期:  2015-04-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭